PDE News and Research

RSS

Mediomics receives additional $460,000 in STTR Phase II grant for PINCER protein assay development

Mediomics, LLC has received an additional $460,000 in a renewal of its 2nd year STTR Phase II grant (R42GM079891) from the National Institute of General Medical Sciences. Since 2007, Mediomics has received over one million dollars of STTR funding to develop its quick and sensitive homogenous PINCER™ protein assay. The major goal of the second year project is to further increase the sensitivity of the biosensor.

28 Jul 2010

CombinatoRx reports $41.3M total revenue for first-quarter 2010

CombinatoRx, Incorporated today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Convergence between EDC and RTSM solutions simplifies workflow management

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today introduced unique product convergence between its DataLabs® EDC solution and ClinPhone® Randomization and Trial Supply Management (RTSM) technologies.

From Parexel 10 Dec 2009

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).

19 Nov 2009

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.

27 Oct 2009

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Biotie announced today that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie.

28 Aug 2009

Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced

Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.

19 Aug 2009

Tadalafil may improve lower urinary tract symptoms in men with benign prostatic hyperplasia

Relative symptom improvement in the IPSS also was significantly better in the tadalafil group. At the end of the study, the proportion of obstructed patients in the placebo group increased, while the proportion in the tadalafil group decreased.

26 Apr 2009

Exercise-induced fatigue in muscular dystrophies, study points to potential new therapies

A University of Iowa study suggests that the prolonged fatigue after mild exercise that occurs in people with many forms of muscular dystrophy is distinct from the inherent muscle weakness caused by the disease.

26 Oct 2008

Researchers examine safety of internet prescriber service providing erectile dysfunction medications

Online Internet shopping today offers many benefits. You can research a product in the privacy of your own home and purchase most anything by clicking a mouse. But should we be allowed to buy prescription drugs via the Internet, bypassing a traditional office visit or conversation with a physician?

12 Aug 2008

Smelling for first time results from knowing abnormalities in congenital loss of smell

New discoveries about the biochemical basis of the majority of cases of the congenital inability to smell any odor, no matter how strong, have enabled their discoverer, Dr. Robert I. Henkin, director of The Taste and Smell Clinic in Washington, DC, to treat such patients, enabling them to smell something for the first time in their lives.

1 May 2007

Outcomes of primary cryotherapy for prostate cancer

In the February 2007 issue of Urology, Dr. Ellis from the Urology Associates of North Texas reports on a large series of patients treated with primary cryotherapy for prostate cancer (CaP).

21 Apr 2007

Sildenafil improves blood flow after heart attack in an animal model

Dogs treated with sildenafil, a drug most commonly used to treat erectile dysfunction, had better blood flow in coronary arteries than control animals, following an induced artery obstruction and treatment that modeled a heart attack and standard medical care given to people

13 Apr 2006

Skin cancer prevention needs to be tackled young

Individuals receive 50% of their total lifetime sun exposure before the age of 18, according to a review article published in Pediatric Dermatology. Therefore, researchers are urging pediatricians to educate children and their families about skin cancer.

14 Feb 2006

Sildenafil reverses symptoms of Raynaud's

German researchers have discovered yet another use for Viagra (sildenafil), they say it relieves the symptoms and improves the circulation of patients with Raynaud's phenomenon.

8 Nov 2005

Viagra's non-blood pressure effect successfully mimics vasopressin action

Normally your kidneys filter about 50 gallons of blood a day, remove such waste as salts and minerals, and concentrate it into urine. When you exercise or don't take in water, your blood "thickens" and instead of removing water, the kidney reverses the process, pulls in water from the body that would normally go into the urine, and puts it into the blood, thus maintaining water balance.

29 Jun 2005

Vascular disease most common cause of male erectile dysfunction

A preeminent cardiologist reports, for the first time in a large prospective study, that certain of his patients with erectile dysfunction (ED) and heart problems can now safely use erection drugs that help up to 80% of men restore function and quality of life.

21 Jun 2005

Viagra protects cardiomyocytes against cell death

Virginia Commonwealth University researchers have shown that a widely used drug for treating erectile dysfunction, Viagra, reduces the death of heart cells under heart attack-like conditions in a laboratory model.

31 Jan 2005